Modelling the epidemiology of infectious diseases for decision analysis: a primer
- PMID: 21504239
- PMCID: PMC7100690
- DOI: 10.2165/11539960-000000000-00000
Modelling the epidemiology of infectious diseases for decision analysis: a primer
Abstract
The number of economic evaluations related to infectious disease topics has increased over the last 2 decades. However, many such evaluations rely on models that do not take into account unique features of infectious diseases that can affect the estimated value of interventions against them. These include their transmissibility from infected to susceptible individuals, the possibility of acquiring natural immunity following recovery from infection and the uncertainties that arise as a result of their complex natural history and epidemiology. Modellers conducting economic evaluations of infectious disease interventions need to know the main features of different types of infectious disease models, the situations in which they should be applied and the effects of model choices on the cost effectiveness of interventions.
Figures




Similar articles
-
Health economic and infectious disease modelling: a guide to merging streams.Pharmacoeconomics. 2011 May;29(5):367-9. doi: 10.2165/11589240-000000000-00000. Pharmacoeconomics. 2011. PMID: 21504238 No abstract available.
-
Merging economics and epidemiology to improve the prediction and management of infectious disease.Ecohealth. 2014 Dec;11(4):464-75. doi: 10.1007/s10393-014-0963-6. Epub 2014 Sep 19. Ecohealth. 2014. PMID: 25233829 Free PMC article.
-
Decision analysis and economic modelling: a primer.Eur J Gastroenterol Hepatol. 2004 Jun;16(6):535-42. doi: 10.1097/00042737-200406000-00005. Eur J Gastroenterol Hepatol. 2004. PMID: 15167154 Review.
-
Simple Inclusion of Complex Diagnostic Algorithms in Infectious Disease Models for Economic Evaluation.Med Decis Making. 2018 Nov;38(8):930-941. doi: 10.1177/0272989X18807438. Med Decis Making. 2018. PMID: 30403578 Free PMC article.
-
Critical issues in the economic evaluation of interventions against communicable diseases.Acta Trop. 2001 Mar 30;78(3):191-206. doi: 10.1016/s0001-706x(00)00176-5. Acta Trop. 2001. PMID: 11311183 Review.
Cited by
-
On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?Pharmacoeconomics. 2020 Nov;38(11):1149-1151. doi: 10.1007/s40273-020-00959-7. Pharmacoeconomics. 2020. PMID: 32924091 Free PMC article. No abstract available.
-
Health economic and infectious disease modelling: a guide to merging streams.Pharmacoeconomics. 2011 May;29(5):367-9. doi: 10.2165/11589240-000000000-00000. Pharmacoeconomics. 2011. PMID: 21504238 No abstract available.
-
Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries.BMC Public Health. 2012 Oct 16;12:878. doi: 10.1186/1471-2458-12-878. BMC Public Health. 2012. PMID: 23072714 Free PMC article.
-
A spatiotemporal simulation study on the transmission of harmful microorganisms through connected healthcare workers in a hospital ward setting.BMC Infect Dis. 2021 Mar 12;21(1):260. doi: 10.1186/s12879-021-05954-7. BMC Infect Dis. 2021. PMID: 33711939 Free PMC article.
-
New methodology for estimating the burden of infectious diseases in Europe.PLoS Med. 2012;9(4):e1001205. doi: 10.1371/journal.pmed.1001205. Epub 2012 Apr 17. PLoS Med. 2012. PMID: 22529750 Free PMC article.
References
-
- Neumann PJ, Fang C-H, Cohen JT. 30 years of pharmaceutical cost-utility analyses. growth, diversity and methodological improvement. 2009;27(10):861–72. - PubMed
-
- WHO . WHO global burden of disease: 2004 update [online] 2010.
-
- World Bank . World development report 1993: investing in health. Oxford: Oxford University Press; 1993.
-
- GAVI Alliance [online]. Available from URL: http://www.gavialliance.org [Accessed 2011 Jan 18]
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical